Radionuclide therapy via SSTR: future aspects from experimental animal studies (Q38008839)

26 August 2017

Radionuclide therapy via SSTR: future aspects from experimental animal studies (English)

1 reference

26 August 2017

Eva Forssell-Aronsson

series ordinal

1

1 reference

26 August 2017

2

1 reference

26 August 2017

Håkan Ahlman

3

1 reference

26 August 2017

4 May 2012

1 reference

26 August 2017

1 reference

26 August 2017

97

1 reference

26 August 2017

86-98

1 reference

26 August 2017

1

1 reference

Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors.

26 August 2017

1 reference

Opportunities in somatostatin research: biological, chemical and therapeutic aspects

21 January 2018

1 reference

Chemotherapy for the carcinoid syndrome

21 January 2018

1 reference

Treatment of the carcinoid tumor and the malignant carcinoid syndrome

21 January 2018

1 reference

Radiation therapy in the management of patients with malignant carcinoid tumors

21 January 2018

1 reference

21 January 2018

1 reference

Radiotherapy for gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

The role of radiation therapy in the treatment of locally unresectable or metastatic carcinoid tumors.

21 January 2018

1 reference

Peptide-receptor radionuclide therapy for endocrine tumors

21 January 2018

1 reference

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.

21 January 2018

1 reference

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour

21 January 2018

1 reference

[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy

21 January 2018

1 reference

Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model

21 January 2018

1 reference

KRJ-I and BON cell lines: defining an appropriate enterochromaffin cell neuroendocrine tumor model.

21 January 2018

1 reference

The functional characterization of normal and neoplastic human enterochromaffin cells

21 January 2018

1 reference

Further delineation of the continuous human neoplastic enterochromaffin cell line, KRJ-I, and the inhibitory effects of lanreotide and rapamycin

21 January 2018

1 reference

A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake

21 January 2018

1 reference

GOT1 xenografted to nude mice: a unique model for in vivo studies on SSTR-mediated radiation therapy of carcinoid tumors

21 January 2018

1 reference

Somatostatin receptor subtype gene expression in human and rodent tumors

21 January 2018

1 reference

A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis

21 January 2018

1 reference

Glucocorticoids increase amylase mRNA levels, secretory organelles, and secretion in pancreatic acinar AR42J cells

21 January 2018

1 reference

111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy

21 January 2018

1 reference

Studies on radiosensitivity from an epidemiological point of view - overview of methods and results

21 January 2018

1 reference

Genetic biomarkers of therapeutic radiation sensitivity

21 January 2018

1 reference

Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1.

21 January 2018

1 reference

Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model

21 January 2018

1 reference

A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours

21 January 2018

1 reference

DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals

21 January 2018

1 reference

Synthesis of DOTA-conjugated multimeric [Tyr3]octreotide peptides via a combination of Cu(I)-catalyzed "click" cycloaddition and thio acid/sulfonyl azide "sulfo-click" amidation and their in vivo evaluation.

21 January 2018

1 reference

SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile

21 January 2018

1 reference

A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors

21 January 2018

1 reference

Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues

21 January 2018

1 reference

Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways

21 January 2018

1 reference

Absence of somatostatin SST(2) receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model

21 January 2018

1 reference

Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors

21 January 2018

1 reference

A novel facile method of labeling octreotide with (18)F-fluorine

21 January 2018

1 reference

Synthesis and evaluation of glycosylated octreotate analogues labeled with radioiodine and 211At via a tin precursor

21 January 2018

1 reference

Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates

21 January 2018

1 reference

213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model

21 January 2018

1 reference

Dosimetric characterization of radionuclides for systemic tumor therapy: influence of particle range, photon emission, and subcellular distribution.

21 January 2018

1 reference

Low-energy electron emitters for targeted radiotherapy of small tumours.

21 January 2018

1 reference

Radiotherapeutic efficacy of (153)Sm-CMDTPA-Tyr(3)-octreotate in tumor-bearing rats

21 January 2018

1 reference

The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours.

21 January 2018

1 reference

Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors

21 January 2018

1 reference

Biokinetics of 111In-DTPA-D-Phe(1)-octreotide in nude mice transplanted with a human carcinoid tumor

21 January 2018

1 reference

Biodistribution and dosimetry of 177Lu-labeled [DOTA0,Tyr3]octreotate in male nude mice with human small cell lung cancer

21 January 2018

1 reference

Biodistribution of 111in-DTPA-D-Phe1-octreotide in tumor-bearing nude mice: influence of amount injected and route of administration

21 January 2018

1 reference

Tumor uptake of 68Ga-DOTA-Tyr3-octreotate: animal PET studies of tumor flow and acute somatostatin receptor modulation in the CA20948 rat model

21 January 2018

1 reference

Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitro

21 January 2018

1 reference

Effects of treatment with (177)Lu-DOTA-Tyr(3)-octreotate on uptake of subsequent injection in carcinoid-bearing nude mice

21 January 2018

1 reference

High interstitial fluid pressure - an obstacle in cancer therapy

21 January 2018

1 reference

Increasing tumor uptake of anticancer drugs with imatinib.

21 January 2018

1 reference

Enhancement of somatostatin-receptor-targeted (177)Lu-[DOTA(0)-Tyr(3)]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation

21 January 2018

1 reference

Radiation-induced apoptosis

21 January 2018

1 reference

New concepts in radiation-induced apoptosis: 'premitotic apoptosis' and 'postmitotic apoptosis'.

21 January 2018

1 reference

Intercellular and intracellular signaling pathways mediating ionizing radiation-induced bystander effects.

21 January 2018

1 reference

Radiation risk to low fluences of alpha particles may be greater than we thought

21 January 2018

1 reference

Mechanism of radiation-induced bystander effect: role of the cyclooxygenase-2 signaling pathway

21 January 2018

1 reference

Apoptosis in neuroendocrine tumours

21 January 2018

1 reference

Death receptors: signaling and modulation

21 January 2018

1 reference

The TRAIL apoptotic pathway in cancer onset, progression and therapy

21 January 2018

1 reference

TRAIL gene therapy: from preclinical development to clinical application

21 January 2018

1 reference

Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1.

21 January 2018

1 reference

Novel ways to sensitise gastrointestinal cancer to apoptosis

21 January 2018

1 reference

Nuclear factor-kappaB activation: from bench to bedside

21 January 2018

1 reference

Anticancer agent CHS 828 suppresses nuclear factor-kappa B activity in cancer cells through downregulation of IKK activity

21 January 2018

1 reference

Anticancer agent CHS-828 inhibits cellular synthesis of NAD.

21 January 2018

1 reference

Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going?

21 January 2018

1 reference

Poly(ADP-ribose): novel functions for an old molecule

21 January 2018

1 reference

Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery

21 January 2018

1 reference

The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors

21 January 2018

1 reference

Antitumoural effects of the pyridyl cyanoguanidine CHS 828 on three different types of neuroendocrine tumours xenografted to nude mice

21 January 2018

1 reference

CHS 828 inhibits neuroblastoma growth in mice alone and in combination with antiangiogenic drugs

21 January 2018

1 reference

New medical strategies for midgut carcinoids

21 January 2018

1 reference

Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data

21 January 2018

1 reference

The RAS signal transduction pathway and its role in radiation sensitivity

21 January 2018

1 reference

Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation

21 January 2018

1 reference

Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors

21 January 2018

1 reference

Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways

21 January 2018

1 reference

Cerebral deafferentiation in operated gliomas as a predictor for malignancy?

21 January 2018

1 reference

Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.

21 January 2018

1 reference

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

21 January 2018

1 reference

Localisation and mechanism of renal retention of radiolabelled somatostatin analogues

21 January 2018

1 reference

Renal uptake and retention of radiolabeled somatostatin, bombesin, neurotensin, minigastrin and CCK analogues: species and gender differences.

21 January 2018

1 reference

Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention

21 January 2018

1 reference

Protein reabsorption in renal proximal tubule-function and dysfunction in kidney pathophysiology

21 January 2018

1 reference

In vitro comparison of renal handling and uptake of two somatostatin receptor-specific peptides labeled with indium-111.

21 January 2018

1 reference

Megalin and cubilin, role in proximal tubule function and during development

21 January 2018

1 reference

Expression of somatostatin in the adult and developing mouse kidney.

21 January 2018

1 reference

Expression of somatostatin receptors 1 and 2 in the adult mouse kidney.

21 January 2018

1 reference

Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney

21 January 2018

1 reference

Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine

21 January 2018

1 reference

Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue

21 January 2018

1 reference

Preclinical and clinical studies of peptide receptor radionuclide therapy

21 January 2018

1 reference

Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues

21 January 2018

1 reference

Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours

21 January 2018

1 reference

Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptides

21 January 2018

1 reference

Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate.

21 January 2018

1 reference

ACE inhibitors and AII receptor antagonists in the treatment and prevention of bone marrow transplant nephropathy

21 January 2018

1 reference

Captopril to mitigate chronic renal failure after hematopoietic stem cell transplantation: a randomized controlled trial

21 January 2018

1 reference

A comparative study of 131I and 177Lu labeled somatostatin analogues for therapy of neuroendocrine tumours

21 January 2018

1 reference

Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model.

21 January 2018

1 reference

Translation of Dosimetric Results of Preclinical Radionuclide Therapy to Clinical Situations: Influence of Photon Irradiation

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000336086

1 reference

26 August 2017

1 reference

PubMed ID

22572526